Tirzepatide and semaglutide are the two most talked-about medications in weight management, and patients often ask which is “better.” Both are FDA-approved, both are highly effective, and they differ in meaningful ways. This article compares them with current data — while being clear that the right choice is an individual medical decision.
How They Differ
Semaglutide works on the GLP-1 pathway. Tirzepatide works on two pathways — GLP-1 and GIP — which is the basis for its often-greater effect on weight in head-to-head data. Both reduce appetite and slow gastric emptying, and both are administered as injections, with oral options emerging in the category. The dual mechanism of tirzepatide is the headline difference.
What the Data Shows
In clinical trials, tirzepatide has produced greater average weight loss at its higher doses than semaglutide, though both achieve results that were unprecedented before this class of medication. Individual responses vary considerably — some people do better on one than the other — and factors beyond raw weight-loss percentages, including side effects, tolerability, cost, and coverage, all matter in the real-world choice.
Beyond Weight Loss
Both medications have shown benefits beyond weight, and their approved indications continue to expand — semaglutide in cardiovascular risk reduction for certain patients, and tirzepatide in sleep apnea, among developments. These broader effects are increasingly part of how physicians choose between them for a given patient.
Frequently Asked Questions
Which causes more weight loss?
Tirzepatide has shown greater average weight loss at higher doses in trials, but individual results vary and the best choice is individual.
Are both FDA-approved?
Yes, both are FDA-approved. At YourMD we prescribe brand-name, FDA-approved GLP-1 medications only.
How do I know which is right for me?
A physician weighs your health history, tolerability, cost, and response. It is a medical decision, not a one-size answer.
Why YourMD Telehealth for Weight Management
At YourMD Telehealth, GLP-1 care is physician-managed and evidence-based. We prescribe FDA-approved, brand-name GLP-1 medications — never compounded versions — with medication obtained through the manufacturer’s own pharmacy programs. A board-certified physician helps determine which option fits you and supports you throughout.
References
- Frías JP, et al. Tirzepatide versus semaglutide (SURPASS-2). New England Journal of Medicine.
- Wilding JPH, et al. Semaglutide for weight management (STEP 1). New England Journal of Medicine.
- Jastreboff AM, et al. Tirzepatide for obesity (SURMOUNT-1). New England Journal of Medicine.
- U.S. Food and Drug Administration. GLP-1 medication prescribing information.